General Principles ICH E8 (R1) for Clinical Studies

Protect clinical study participants by upholding the four pillars of subject protection: ethical conduct, confidentiality, safety information, and patient focus, aligned with ICH E6 (R1) principles.

Implement quality by design in clinical studies by balancing proactive design with retrospective learning, focusing on four elements, predefined objectives, and well-defined endpoints.

Define critical to quality factors in clinical studies per ICH E8 (R1), linking patient protection, reliable results, and risk-based decisions across protocol design, feasibility, safety, and reporting.

Identify critical to quality factors through a collaborative, open-dialogue approach that blends soft skills and technical design questions, guiding feasibility, patient input, and risk-based data collection for quality by design.

Plan drug development by adhering to scientific principles and good study design, coordinating with regulatory authorities, and incorporating post-approval studies, biomarkers, and regional health technology assessments.

Identify critical to quality factors for an investigational medicinal product by thorough characterization of the IMP, its formulation, and any administration device, within a development plan.

Bridge non-clinical studies to clinical trials with quality by design, ensuring sufficient non-clinical information supports initial human doses and exposure duration while identifying gaps that affect timing and scope.

Optimize clinical development planning using adaptive designs and real world evidence. Identify drug characteristics early, refine dose and endpoints, and focus on critical to quality factors across studies.

Discover how additional development extends the clinical studies lifecycle, covering new indications, populations, dosage regimens, routes of administration, or combinations, and rechecking critical to quality factors with prior study data.

Describe how a clinical development plan evolves from preclinical data through exploratory and confirmatory studies, addressing critical to quality factors: design, safety, feasibility, study conduct, reporting, and third-party engagement.

Explore the background and rationale of quality by design in clinical studies, detailing data sources, study design options, and the central role of randomized interventional studies.

Define the study population with clear inclusion and exclusion criteria to align with objectives and study design stages: exploratory, confirmatory, and post-approval.

Describe clearly all treatments, controls, doses, dosage regimens, and concomitant or background treatments, aligned with study objectives, define naive patients and a treatment-free time frame to support quality factors.

Choose the right control group to separate treatment effects from disease progression and other care, using internal or external controls with bias-aware planning.

Clarify what a response variable is and distinguish primary, secondary, and exploratory endpoints. Align endpoint choice with the study objective, timing, patient feasibility, and drug knowledge.

Identify and mitigate bias in clinical studies by evaluating blinding types, recognizing intercurrent events, and applying pre-specified rules and sensitivity analyses to ensure reliable results.

Engage early with statisticians to design and document the protocol and the statistical analysis plan, detailing the analysis of primary and secondary endpoints, interim analyses, missing data, and confounding factors.

Explore study data, including primary data from case report forms, labs, and patient-reported outcomes, and secondary data from external sources. Ensure data quality, protection, and use of international standards.

Identify critical to quality factors in study conduct per ich e8 (r1), ensure protocol adherence, apply quality by design, and safeguard interim data through centralized monitoring.

Establish safety monitoring to identify, monitor, and report concerns, protect participants, set withdrawal criteria in the protocol, and form a data monitoring committee to review data and preserve study integrity.

Align study reporting with E3 format and quality by design, delivering a factual, objective report with safety information and informed consent details, disclosed by the investigator and registered on ClinicalTrials.gov.

Technology evolves, enabling new study designs and broader data sources. Regulators safeguard subjects under the Declaration of Helsinki, keeping innovation aligned with ICH E8 (R1) and quality by design.